FDA 483 - RJ General Corporation - January 12, 2022

An FDA inspection of RJ General Corporation, a drug repackager in Cincinnati, OH, revealed significant deficiencies in its quality control unit and batch production records. The firm lacks a defined quality control unit, written procedures for its responsibilities, and proper documentation for critical production steps. These issues indicate a lack of adequate controls to ensure drug product quality and compliance with GMP requirements.